Search
for
Sort by
Research 91–120 of 1000+
- Immune Regulation in Hair Follicle Protection and Hair Regeneration: Insights from the Collapse of Immune Privilege in Alopecia Areata and Targeted Immunotherapy
- Alopecia areata
- Emerging treatments in alopecia
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Targeted immunotherapy for hair regrowth and regeneration
- Janus Kinase inhibitors in dermatology: a review
- Efficacy of Janus kinase inhibitors in adult patients with alopecia areata
- Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
- At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- A review of Janus kinase inhibitor use in scarring alopecia
- Inibidores das Janus Associated Kinases na Terapêutica Farmacológica
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- The Current State of Patient Adherence to Lab Monitoring Guidelines for Janus Kinase Inhibitors in Patients with Alopecia Areata.
- BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
- 0527 Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review
- Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- Janus kinase inhibitors for alopecia areata: A narrative review
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors